Compare Oscar Health Inc (OSCR) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs T Rowe Price Group Inc — how do they compare? Oscar Health Inc trades at $31.71 (market cap $10.19B), while T Rowe Price Group Inc trades at $107.71 (market cap $23.34B). The key difference: T Rowe Price Group Inc is far larger — about 2.3× Oscar Health Inc's market cap, and T Rowe Price Group Inc pays a 4.75% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| OSCR | TROW | |
|---|---|---|
Market Cap | $10.19B | $23.34B |
Sector | Health | Financials |
52-Week High | $33.01 | $121.68 |
52-Week Low | $10.85 | $86.19 |
Enterprise Value | $6.54B | $20.54B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oscar Health (OSCR) trades at $33.01, up 2.36% today and approaching its 52-week high of $33.10. The stock shows strong technical momentum with bullish moving averages and has surged 109% year-to-date. Fundamentally, revenue grew from $11.7B in 2025 to $15.3B in 2026, with net income turning positive at $551M. Recent earnings beats and membership growth to 2.96 million support the bullish case, though valuation metrics like P/E of 25.39 and P/B of 4.97 suggest premium pricing.
Outlook remains positive with strong revenue growth and profitability improvements, but risks include high valuation multiples and dependence on sustained membership growth. Analyst consensus is mixed with 27% buy ratings and a $30.67 price target below current levels, indicating caution despite technical strength. Key catalysts include continued operational efficiency gains and AI integration, while medical cost management remains critical.
T. Rowe Price (TROW) trades at $109.42, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 10.99, net income margin of 29.26%, and consistent dividend payments. Recent developments include the acquisition of F/m Investments to expand fixed-income ETF capabilities and significant AI adoption across operations. Revenue has grown from $6.5B in 2022 to $7.3B in 2025, with net income reaching $2.09B.
TROW presents a mixed outlook with attractive valuation metrics and solid profitability offset by bearish technical indicators and equity outflows. The consensus price target of $112.50 suggests modest upside potential. Key risks include market-sensitive revenue streams and competitive pressures in asset management. Institutional buying from firms like BlackRock provides support, but investors should weigh the strong fundamentals against near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
